TIPS with half-dose Donafenib for liver cancer with portal hypertension
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment that combines a procedure called TIPS with a targeted therapy drug (Donafenib) at half strength. It is for people with advanced liver cancer that has spread into the portal vein and caused high blood pressure in the liver (portal hypertension). The goal is to see if this combination can help control the cancer and reduce complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have liver cancer (hepatocellular carcinoma) that has not been treated before.
- Your cancer must be advanced and have caused a blood clot in the main vein of your liver (portal vein tumor thrombus), leading to high blood pressure in that area.
- You should be in generally good health (able to do daily activities) and have at least 3 months to live.
- Your blood cell counts, liver and kidney function must be within certain ranges.
- You should have had a complication from portal hypertension, like bleeding in your stomach or esophagus, or a large amount of fluid in your belly that does not go away easily.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding the immunotherapy drug cadonilimab (and a related treatment plan) plus TIPS can help people with advanced liver cancer that has a tumor clot causing portal vein pressure problems. It aims to improve disease control while managing the circulation pressure in the liver.
This study looks back at patients who received a combination of donafenib (a targeted pill), immunotherapy (a medicine that helps your immune system fight cancer), and a liver-directed procedure (TACE or HAIC) as their first treatment for liver cancer that can't be surgically removed. The goal is to check how well this combination works and how safe it is.
This trial tests whether giving medicine directly into the liver blood vessels before surgery can improve survival for people with liver cancer that has a blockage (tumor in the portal vein). It compares this approach plus surgery versus surgery alone in a randomized study.
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
This study tests a combined treatment for liver cancer that cannot be removed with surgery. It combines a targeted therapy pill (donafenib) with a procedure that delivers chemotherapy directly to the tumor (E-TACE). The goal is to see if this combination helps control the cancer and is safe for patients.
This trial combines a procedure called TIPS (which helps relieve pressure in the liver) with two drugs—lenvatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—for people with advanced liver cancer that has spread into the main vein of the liver. It aims to see if this combination can help control the cancer and improve symptoms.
Hear when a new Hepatocellular Carcinoma with PVTT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.